Clinical efficacy of teicoplanin against MRSA infections in emergency and critical care medicine

Japanese Journal of Chemotherapy

Volumn 51, Issue 8, 2003, Pages 490-496

  Ueda, Yasuharu ^a   Shibata, Yasushi ^a   Ogawa, Futoshi ^a   Harada, Naoshige ^a   Yamamoto, Yasuhiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

MRSA; Teicoplanin

Indexed keywords

CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; FLOMOXEF; MEROPENEM; METICILLIN; PIPERACILLIN; SPARFLOXACIN; TEICOPLANIN;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG USE; EMERGENCY MEDICINE; ERADICATION THERAPY; FEMALE; HUMAN; INTENSIVE CARE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PLEURISY; PNEUMONIA; PSEUDOMONAS AERUGINOSA; SEPTICEMIA; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STEADY STATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0041826749     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Neu H C, Labthavikul P: In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother 24: 425-428, 1983
2. Pallanza R, Berti M, Goldstein B P, et al.: Teicoplanin: in vitro and in vivo evaluation in comparison with other antibiotics. J Antimicrob Chemother 11: 419-425, 1983
3. Greenwood D: Microbiological properties of teicoplanin. J Antimicrob Chemother 21: 1-13, 1988
4. 14C-teicoplanin in healthy volunteers. J Antimicrob Chemother 21 (Suppl A): 23-28, 1988
5. Sahai J: Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome". Antimicrob Agents Chemother 34: 765-769, 1990
6. Poirier T I, Giudici R A: Survey of clinical pharmacokinetic software for microcomputers. Hosp Pharm 27: 971-977, 1992
7. Lewis P, Garaud J J, Parenti F: A multi-centre open clinical trial of teicoplanin in infections caused by Gram-positive bacteria. J Antimicrob Chemother 21 (Suppl A): 61-67, 1988
8. Chambers HF, Kennedy S: Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 34: 510-514, 1990
9. MacGowan A P, McMullin C M, White L O, et al.: Serum monitoring of teicoplanin. J Antimicrob Chemother 30: 399-402, 1990
10. Livornese L L, Gold M, Johnson C C, et al.: Clinical evaluation of teicoplanin in the treatment of Gram-positive bacterial intravascular infections. J Antimicrob Chemother 31: 188-191, 1993
11. Fauser A A, Lang E, Dolken G, et al.: Treatment of severe sepsis in bone marrow transplant recipients with teicoplanin in combination with β-lactams and aminoglycosides. Infection 19: 195-200, 1991
12. Van der Auwera P, Aoun M, Meunier F: Randomised study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother 35: 451-457, 1991
13. Charbonneau P, Harding I, Garaud J J, et al.: Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infectious in intensive care patients. Int Care Med 20: S35-S42, 1994